

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Moses CHAO et al.

Art Unit: 1647

Application No.: 10/021,571

Conf. No. 9320

Examiner: C. F. Nichols

Filed: December 19, 2001

Washington, D.C.

For: A TRANSMEMBRANE PROTEIN AS A DOWNSTREAM TARGET OF...

Atty.'s Docket: CHAO=11A

Date: January 21, 2003

FAX RECEIVED

JUN 26 2003

GROUP 1600

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is a ☒ Amendment []

in the above-identified application.

☒ Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[] No additional fee is required.

☒ The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		PRESENT EXTRA EQUALS
TOTAL	* 7	MINUS	** 34		0
INDEP.	* 2	MINUS	*** 3		0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 42	\$
+ 140	\$
ADDITIONAL FEE TOTAL	
	\$

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 84	\$
+ 280	\$
TOTAL	
	\$

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

☒ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity
Response Filed Within

☒ First - \$ 55.00

[] Second - \$ 200.00

[] Third - \$ 460.00

[] Fourth - \$ 720.00

Month After Time Period Set

Other Than Small Entity
Response Filed Within

[] First - \$ 110.00

[] Second - \$ 400.00

[] Third - \$ 920.00

[] Fourth - \$ 1440.00

Month After Time Period Set

[] Less fees (\$) already paid for month(s) extension of time on

[] Please charge my Deposit Account No. 02-4035 in the amount of \$.

☒ Credit Card Payment Form, PTO-2098, is attached, authorizing payment in the amount of \$ 55.00.

[] A check in the amount of \$ is attached (check no.).

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.18 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

By: 

Allen C. Yun
Registration No. 37,971

Facsimile: (202) 737-3528
Telephone: (202) 628-6167


FAX RECEIVED

JUN 26 2003

GROUP 1600

APPLICATION/PATENT NO: 10/621,571
DOCKET NO: CHAD = 11ATHE PATENT AND TRADEMARK OFFICE STAMP
HEREON ACKNOWLEDGES RECEIPT OF THE
FOLLOWING PAPERS:

- ☒ FEES \$ 55.00
- ☒ PTO FORM 2038 ☐ (CH. # _____)
- ☒ EXTENSION OF TIME (_____) MONTHS)
- ☐ TRANSMITTAL LETTER
- ☐ MISSING PARTS RESPONSE WITH DECL
- ☒ AMENDMENT/RESPONSE (circle one)
- ☐ PRELIMINARY ☐ SUPPLEMENTAL
- ☐ APPLICATION DATA SHEET
- ☐ RESTRICTION/ELECTION REPLY
- ☐ SEQUENCE LISTING ☐ WITH DISK
- ☐ RCE / CPA TRANSMITTAL (circle one)
- ☐ NOTICE OF APPEAL
- ☐ APPEAL BRIEF (TRIPPLICATE)
- ☐ REPLY BRIEF (TRIPPLICATE)
- ☐ OTHER _____

CONF. NO.: 9320
CLIENT CODE: N4004

- ☐ ASSIGNMENT
- ☐ INFORMATION DISCLOSURE STATEMENT
- ☐ FORM SB08A & _____ PATENTS/PUBS
- ☐ PRIORITY DOCUMENT(S) NO. _____
- ☐ DECLARATION UNDER \$ _____
- ☐ LETTER TO DRAFTSMAN
- ☐ _____ SHEETS OF DRAWINGS
- ☐ ISSUE FEE TRANSMITTAL FORM
- ☐ MAINTENANCE FEE LETTER

B&N-1

FAX RECEIVED

JUN 26 2003

GROUP 1600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit: 1647
Moses CHAO et al.)	Examiner: C. F. Nichols
Appln. No.: 10/021,571)	Washington, D.C.
Filed: December 19, 2001)	June 26, 2003
For: A TRANSMEMBRANE PROTEIN AS)	Atty. Docket: CHAO=11A
A DOWNSTREAM TARGET OF...)	
Confirmation No.: 9320)	BY FACSIMILE

COMMUNICATION

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Mail Stop
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202


Sir:

This will certify that the copy of the Amendment of January 21, 2003, re-filed by fax herewith, is a duplicate copy of the Amendment of January 21, 2003, originally filed on January 21, 2003.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By


Allen C. Yun
Registration No. 37,971

ACY:pp
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528

C:\BFI\W\yun\chao11a\pto\communication.doc

FAX RECEIVED

JUN 26 2003

GROUP 1600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Moses CHAO et al.

Appln. No.: 10/021,571

Filed: December 19, 2001

For: A TRANSMEMBRANE PROTEIN AS
A DOWNSTREAM TARGET OF...

Confirmation No.: 9320

Art Unit: 1647

Examiner: C. P. Nichols

Washington, D.C.

January 21, 2003

Atty. Docket: CHAO=11A

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of December 3, 2002, Paper No. 6, primarily in the nature of a restriction requirement, petition and payment for a one month extension of time being attached hereto, please amend as follows:

IN THE CLAIMS

Please replace claim 1 with new amended claim 1 as follows below. A marked up version of the amended claim to show the changes made is attached hereto.

1(Amended). An isolated polypeptide, which associates with TrkA and p75 neurotrophin receptors, is a target for phosphorylation by neurotrophin and ephrin receptor tyrosine kinases, enhances neurotransmitter release, and modulates the